SEC Tracker
Get the app
FLGT · XBRL financial data

Fulgent Genetics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FLGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers8571*64717276*73828483*7185
Cost of revenue4545*42454544*45474951*5060
Gross profit4025*22262732*28343633*2126
Research and development1012*11131212*12131414*1415
General and administrative1732*21212124*25262342*2827
Total operating expenses40176*44454448*48545169*5662
Operating income (loss)0(151)*(22)(19)(17)(16)*(20)(20)(15)(36)*(35)(36)
Interest income66*7888*8887*96
Interest expense0(0)*(0)000*0000*00
Other income (expense)0(0)*(0)010*00(0)0*00
Income tax expense (benefit)20(11)*(0)(2)(4)(2)*0(2)(1)(6)*(1)0
Net income (loss)(13)(128)*(13)(9)(15)(6)*(12)(19)(7)(23)*(25)(30)
Weighted average shares, basic millions of shares3030*30303031*31313131*3128
Weighted average shares, diluted millions of shares3030*30303031*31313131*3128

Balance sheet

CSV

Fiscal quarters (FLGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents8497556558556788118502326
Marketable securities—————203———286253231
Marketable securities, non-current384424540526602570494484412369328294
Accounts receivable495152575769717771856965
Inventory——————————11
Total current assets550508387399327354417429507550479455
Property and equipment, net85838793107106107110112113116113
Right-of-use asset12119965555587
Goodwill1422222222222222225255454
Total assets1,3581,2351,2301,2321,2341,2201,2061,2001,2151,2141,1561,089
Accounts payable161520202018181918192116
Accrued liabilities213126262424172223343524
Total current liabilities617376767473667172859072
Lease liability, non-current877754444466
Total liabilities97102103103999183889410711293
Retained earnings761633620611596590579560553530505476
Total stockholders' equity1,2591,1361,1301,1331,1381,1331,1271,1171,1261,1121,0501,002
Total liabilities and equity1,3581,2351,2301,2321,2341,2201,2061,2001,2151,2141,1561,089
Common shares outstanding (cover page) millions of shares303030303131303131312828

Cash flows

CSV

Fiscal quarters (FLGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(13)(128)*(13)(9)(15)(6)*(12)(19)(7)(23)*(25)(30)
Stock-based compensation11*11*1212*11*10*1110*10*9*109*
Depreciation and amortization67*7666*66*6*6*68*
Net cash from operating activities10*15*74*(16)*25*(4)(30)*11*year only7(24)*
Purchases of property and equipment5*3*413*20*4*57*6*5*54*
Net cash from investing activities20*24*(47)7*9*(27)*2853*19*11*1151*
Share repurchases—23*00*0*0*92*0*0*4024*
Net cash from financing activities(4)*(26)*(3)(1)*(1)*(0)*(11)(3)*(0)*(1)*(45)(24)*
Net change in cash26*13*(43)10*(7)*(3)*1221*30*(67)*(27)3*

Compare with peers

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Fulgent Genetics2685(24)*27.5M10.8 quarters 10-QJun 30, 2026
BillionToOne562123not reportednot reported— 10-QSep 30, 2026
Fortrea Holdings22169261*96.5M— 10-QSep 30, 2026
Celcuity182not reported(55)*48.9M13.6 quarters 10-QJun 30, 2026
Exagen25204*24.2M— 10-QJun 30, 2026
Castle Biosciences6210415*30.5M— 10-QJun 30, 2026
Personalis9826(27)*108.4M6.7 quarters 10-QSep 30, 2026
Lumexa Imaging Holdings7026433*96.1M— 10-QJun 30, 2026
Freenome0.4not reported(0.1)*not reported3.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.